HIMS HERS HEALTH INC CLASS A (HIMS)
Health Care · digital health / telehealth · NYSE
A consumer-first digital health platform transforming the fulfillment of healthcare services and wellness products through an integrated telehealth and pharmacy model.
What HIMS HERS HEALTH INC CLASS A does
Hims & Hers Health is a digital health platform that connects consumers with licensed healthcare professionals to provide personalized treatments and wellness products. Its platform integrates a provider network, electronic medical records, digital prescriptions, and cloud-enabled pharmacy fulfillment. The company focuses on conditions including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health.
Themes: telehealth, e-commerce pharmacy, personalized medicine, weight loss drugs, digital health platform
Fundamentals
- Price$28.06 as of 2026-10-08 close
- Market cap$6.5B as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return-51.8% 2025-10-08 close $58.17 → 2026-10-08 close $28.06
- P/En/a negative earnings
- Net margin+5.5% FY2025, SEC XBRL
- Gross margin+73.8% FY2025, SEC XBRL
- ROE+23.7% FY2025, SEC XBRL
- Debt / equity2.18 as of 2026-09-03
- Revenue growth (YoY)+32.8% as of 2026-09-03
- Revenue CAGR (3y)+64.5% SEC XBRL
- Beta2.36 as of 2026-09-03
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How HIMS compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How HIMS HERS HEALTH INC CLASS A looks technically
HIMS HERS HEALTH INC CLASS A (HIMS) is trading 1.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 46 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 34 trading days ago. It is 57.0% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
9
| Distance from the 200-day | it is trading 1.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $29.37 | $29.37 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $27.69 | $27.69 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 31.03. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 46 trading days ago — a "golden cross", a bullish long-term signal | 46 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.3% above | +1.3% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($27.31 to $31.81) — its "stochastic" reading is 17 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 16.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $65.30 | $65.30 |
|---|---|---|
| From the 52-week high | it is 57.0% below its 52-week high (its highest price of the past year) | -57.0% |
| Above the 52-week low | it is 104.2% above its 52-week low (its lowest price of the past year) | +104.2% |
| Below the 52-week high | it is 57.0% below its highest point of the past year | 57.0% |
| Since a 20-day breakout | it made a new 20-day high about 34 trading days ago | 34 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $72.98 (set on 2025-02-19) | $72.98 |
| Given back of the 52-week move | over the past year its closes ranged ($14.52 to $62.76), and it has recovered roughly a quarter of its fall from last year’s high — 28% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $44.33 to $45.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 28.1% |
| From the all-time high | it is 61.6% below its all-time high | -61.5% |
| Nearest price level | it is trading 2.3% above a support level at $27.41 — a price it turned at three times since 2026-03-11, most recently on 2026-09-24. Since 2024-10-08 it has 2 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.3% |
| All-time low | its lowest closing price on record is $2.72 (set on 2022-05-12) | $2.72 |
| Above the all-time low | it is 931.6% above its all-time low | +931.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 1st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.65 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.65 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $27.32 and $30.41 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $27.32 – $28.86 – $30.41 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.9% |
| Stretch from the 200-day average | it is trading 0.2 daily ranges above its 200-day average price (1.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.54× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.4% since the prior reading | -0.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.01 toward buy |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Open gap | it gapped 4.0% below the previous close 32 sessions ago and has not traded back through the level it left behind at 33.78 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.0% |
| Gap filled | a 2.0% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.4 percentage points (the stock lost 0.4% while the market gained 1.0%) | -1.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 26.0 percentage points (the stock lost 22.2% while the market gained 3.8%) | -26.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 20.6 percentage points (the stock gained 38.0% while the market gained 17.5%) | +20.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 66.7 percentage points (the stock lost 51.8% while the market gained 15.0%) | -66.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.5% of the share price. | -7.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $25.66 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +9.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $29.55 — a volume-weighted average of daily closes over 43 sessions, not a true tick-by-tick VWAP. | -5.0% |
Price levels it has turned at before
HIMS last closed at $28.06 on 2026-10-08. Since 2024-10-08 it has turned at 2 prices below its last close and 11 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $27.41 | Support | 2.3% below the last close | turned there three times · 2026-03-11 to 2026-09-24 |
| $30.26 | Resistance | 7.8% above the last close | turned there four times · 2024-11-13 to 2026-06-25 |
| $31.02 | Resistance | 10.6% above the last close | turned there twice · 2025-03-13 to 2026-09-30 |
| $31.83 | Resistance | 13.4% above the last close | turned there twice · 2026-04-20 to 2026-09-22 |
| $24.03 | Support | 14.4% below the last close | turned there five times · 2024-10-22 to 2026-07-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $31.03.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 6 trading days, since 2026-10-01.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.80 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$31.15 range $23.00 – $42.00; median $31.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HIMS
- Consensus EPS estimate$0.1537 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.06255 from $0.09112, on 2026-09-04, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on third-party licensed pharmacies and provider networks for operations and compliance.","Regulatory environment related to telehealth and prescription medications is complex and subject to change.","Operating in highly competitive markets with potential for price pressure and shifting consumer demand."]
What changed in the latest 10-Q
AI-assisted comparison of HIMS's 10-Q filed 2026-05-11 against the prior one filed 2025-11-03.
Risk Factors
- Added:
- Added risk factor: 'Acquisitions and investments could result in operating difficulties, dilution, and other harmful consequences that may adversely impact our business, financial condition, and results of operations. Additionally, if we are not able to identify and successfully acquire suitable businesses, our results of operations and prospects could be harmed.' (filed 2026-05-11)
- Added risk factor: 'Expansion into international markets is important for our growth, and as we expand internationally, we will face additional business, political, legal, regulatory, operational, financial, and economic risks, any of which could increase our costs and hinder such growth.' (filed 2026-05-11)
- Added risk factor: 'We have been, and in the future may be, subject to actions and public statements by U.S. federal and state government officials and agencies, which could materially and adversely affect our business, financial condition, results of operations and reputation.' (filed 2026-05-11)
- Added risk factor: 'Disruption to our global supply chain, including as a result of evolving laws and regulations, can impact our operations in ways that may be difficult to predict or control, may require us to modify or discontinue certain supplier relationships, sourcing strategies, or operational processes, and may result in delays in product availability, increased costs for compliance or alternative sourcing, or the need to shift to different third-party partners.' (filed 2026-05-11)
- Removed:
- Removed from Summary of Principal Risk Factors: 'We may not be able to maintain our profitability.' Language changed to 'We may not be able to maintain our profitability in any given period.' (filed 2026-05-11)
- Removed detailed supply chain and regulatory risk language that was previously integrated in the regulated environment risk factor and relocated to a separate risk factor (filed 2026-05-11)
- Removed from risk factor: 'From time to time we are subject to legal proceedings in the ordinary course of business, which can include intellectual property disputes or claims relating to our marketing or sale of products, any of which may be costly to defend and could materially harm our business and results of operations.' Language expanded to include 'legal and regulatory proceedings and inquiries' (filed 2026-05-11)
- Reworded:
- Changed 'We may not be able to maintain our profitability.' to 'We may not be able to maintain our profitability in any given period.' in Summary of Principal Risk Factors (filed 2026-05-11)
- Changed 'The market price of our Class A common stock may be volatile.' to 'The market price of our Class A common stock has been and may continue to be volatile.' in Summary of Principal Risk Factors (filed 2026-05-11)
- Separated and restructured supply chain and regulatory compliance language. Older filing combined supply chain disruption discussion within the regulated environment risk factor; newer filing creates separate risk factor for global supply chain disruptions (filed 2026-05-11)
- Changed 'From time to time we are subject to legal proceedings' to 'From time to time we are subject to legal and regulatory proceedings and inquiries' (filed 2026-05-11)
- Updated financial metrics in detailed risk discussion: newer filing shows revenue growth to $2,347.6 million for year ended December 31, 2025 and 2,442 employees as of December 31, 2025; older filing showed revenue of $1,476.5 million for year ended December 31, 2024 and 1,637 employees as of December 31, 2024 (filed 2026-05-11 vs 2025-11-03)
- Notes:
- The newer filing text provided appears truncated at the end of the 'Risks Related to Our Business' section, limiting complete comparison of the detailed risk discussion paragraphs
- The older filing text also appears truncated at the end of the detailed risk discussion, limiting full comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 13 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 7 sells ($2M) — 4 selling insiders
- Last 90 days · read to 2026-10-040 buys · 13 sells ($4M) — 5 selling insiders
- Last 180 days · read to 2026-10-041 buy ($1M) · 26 sells ($12M) — 1 buying, 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about HIMS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for HIMS from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding HIMS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 61,258,213
- Reported value $2,123,822,238
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about HIMS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
HIMS had 52,920,443 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for HIMS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 52,920,443
- Prior settlement (shares) 54,945,417
- Reported change -3.69%
- Days to cover (reported) 6.13
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teladoc Health (TDOC)
- Ro
- Amazon Pharmacy (AMZN)
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- GoodRx Holdings (GDRX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HIMS vs…
HIMS HERS HEALTH INC CLASS A is found in…
Frequently asked questions
What does HIMS HERS HEALTH INC CLASS A (HIMS) do?
Hims & Hers Health is a digital health platform that connects consumers with licensed healthcare professionals to provide personalized treatments and wellness products. Its platform integrates a provider network, electronic medical records, digital prescriptions, and cloud-enabled pharmacy fulfillment. The company focuses on conditions including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health.
What sector is HIMS HERS HEALTH INC CLASS A (HIMS) in?
HIMS HERS HEALTH INC CLASS A (HIMS) is classified in the Health Care sector. Its industry is digital health / telehealth. It trades on NYSE.
Who are HIMS HERS HEALTH INC CLASS A's (HIMS) competitors?
Notable peers of HIMS HERS HEALTH INC CLASS A (HIMS) include Teladoc Health, Ro, Amazon Pharmacy, CVS Health and Walgreens Boots Alliance. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in HIMS?
Yes — we hold 1 matched STOCK Act disclosure for HIMS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is HIMS HERS HEALTH INC CLASS A (HIMS) overbought or oversold right now?
HIMS HERS HEALTH INC CLASS A (HIMS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HIMS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.